Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: A multicenter cross-sectional observational studyopen access

Authors
Lee, Sang-HoonKim, Yong-GilLee, Seung-GeunLee, Soo HyunKim, Young-JooJeon, Ja-YoungJo, Joo-YoungYoo, Hyun-JeongLee, JuneyoungKim, Tae-Hwan
Issue Date
5월-2022
Publisher
WILEY
Keywords
ankylosing spondylitis; patient satisfaction; productivity loss; treatment pattern; tumor necrosis factor inhibitor
Citation
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, v.25, no.5, pp.523 - 531
Indexed
SCIE
SCOPUS
Journal Title
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
Volume
25
Number
5
Start Page
523
End Page
531
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/143086
DOI
10.1111/1756-185X.14304
ISSN
1756-1841
Abstract
Aim To provide in-depth understanding of real-world tumor necrosis factor inhibitor (TNFi) treatment patterns in patients with ankylosing spondylitis (AS) and treatment satisfaction, productivity loss, and associated factors. Methods This was a multicenter observational hybrid retrospective chart review and cross-sectional survey study. Disease activity and physical functioning were measured using the Bath AS Disease Activity Index and Bath AS Functional Index, respectively. Treatment satisfaction was determined with the Treatment Satisfaction Questionnaire for Medication (TSQM). Productivity loss was evaluated using the Korean version of the World Health Organization-Health and Work Performance Questionnaire. Results A total of 497 patients were enrolled (mean age 40.3 years, 85.3% male, mean AS duration 10 years). The mean duration of TNFi treatment was 6.2 years. Among the four TNFi considered, adalimumab (39.6%) and etanercept (23.5%) were most commonly used at study enrollment. The TSQM convenience domain score was lower than scores in the effectiveness, adverse effects, and global satisfaction domains. Subcutaneous syringe-type injection and intravenous injection were associated with lower patient convenience satisfaction than subcutaneous pen-type injection. Increased costs of lost productivity time were associated with female sex, unemployed status, and higher disease activity. Conclusions The most frequently prescribed TNFi was adalimumab, followed by etanercept. Etanercept was used for the longest duration. More convenient treatment options may enhance overall treatment satisfaction. Considerable loss in productivity due to AS was observed in this study. To reflect patients' perspectives, further attention should be paid to factors associated with treatment satisfaction and productivity loss when selecting treatment options.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE